報價延遲最少15分鐘:2025/05/31 19:53 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.78 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-4.12/-17.42
|
|
企業價值
13.36M
|
| 資產負債 |
|
每股賬面淨值
0.91
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
536.36K
|
|
每股收益
0.04
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/31 19:53 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft. |